• Silo Pharma priced an at-the-market private placement issuing 619,965 shares or pre-funded warrants, paired with Series A-3 and A-4 warrants.
• Warrants cover 619,965 shares each; exercise price USD 6.21; exercisable immediately upon issuance.
• Series A-3 warrants expire five years after the effective date of the Resale Registration Statement; Series A-4 warrants expire 18 months after.
• Gross proceeds expected at about USD 4 million upfront; warrant exercise could add about USD 7.7 million in cash proceeds.
• Registration rights agreement requires filing SEC resale registration statement covering resale of the unregistered securities.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Silo Pharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607100800PRIMZONEFULLFEED9760178) on July 10, 2026, and is solely responsible for the information contained therein.